Skip to Content
scroll

Telix Pharma Ltd (TLX)

ASX.TLX $4.64

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

ASX.TLX $4.64

20 MINUTE DELAYED

TODAY

2.43 %

1 YEAR RETURN

0.00%

VOLUME

463,907

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

3.55

8.82

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

4.64

Change

0.11 (2.43)

Bid / Ask

4.63 - 4.66

Volume

463,907

Volume (3mths avg)

0

Turnover

2,170,493

Open

4.60

Day Range

4.60 - 4.75

VWAP

4.68

Prev Close

4.53

Last Trade

06.10 01/07 (AEST)

i

KEY INFORMATION
Sector

Shares Issued

0

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

Dividend Pay Date

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

Yield %

0.00

Market Cap

0.00

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
OPINION
ACTION
image description

Business Summary

Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. Its lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.
image description

Relevant suggested news and content from the site

Back to top